CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.
Frequently asked questions
What sector does Cellsource Co Ltd (4880) operate in?
Cellsource Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cellsource Co Ltd (4880) current stock price?
As of the latest data, Cellsource Co Ltd stock price is ¥323, with a previous close of ¥323.
What is Cellsource Co Ltd (4880) current market capitalization?
Cellsource Co Ltd market cap is approximately 6.41 billion.
What is Cellsource Co Ltd (4880) Earnings Per Share (EPS)?
The trailing EPS is ¥4, and the forward EPS is ¥6.
What is Cellsource Co Ltd (4880) Price-to-Earnings (P/E) ratio?
Cellsource Co Ltd current P/E ratio is 90.73, with a forward P/E of 58.73.
What is Cellsource Co Ltd (4880) EBITDA?
Cellsource Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 53.52 million.
Does Cellsource Co Ltd (4880) pay dividends?
Yes. Cellsource Co Ltd pays annual dividends with an annualized yield of 1.55% and an estimated annual payout of ¥5 per share.
When is the next ex-dividend date for Cellsource Co Ltd (4880)?
The next ex-dividend date is scheduled for October 30, 2026.
What is Cellsource Co Ltd (4880) beta (volatility) score?
Cellsource Co Ltd has a beta of -0.092, indicating lower volatility than the overall market.
